Answers are grounded in this paper and cite their sources.
Phenotype-driven gene prioritisation relies on matching the Human Phenotype Ontology (HPO) terms recorded by clinicians to phenotype-gene associations held in knowledge resources. How physicians phenotype patients varies widely, and this heterogeneity is poorly captured by existing resources, limiting diagnostic performance. We characterised phenotyping practice in 1,686 patients with a confirmed genetic diagnosis from four international cohorts, and in a prospective experiment in which 12 clinical geneticists encoded the same three clinical reports in HPO terms. We built PhenoGenius, a symptom co-occurrence model derived from phenotype-gene associations collected from HPO-structured databases and from text mining of OMIM, MedGen and PubMed, combining a node-similarity graph and non-negative matrix factorisation. We benchmarked PhenoGenius against seven phenotype-driven gene prioritisation tools and two reasoning language models (OpenAI o3 and Gemini 2.5 Pro), and evaluated it on 4,716 curated case reports from the GA4GH Phenopacket Store. Only 43% of the 11,526 gene-phenotype associations recorded in the cohort were present in HPO-structured databases. Among patients sharing the same causal gene, only 22.7% of annotations were reused even when any ancestor or descendant term was allowed; when different physicians encoded the same report, 47.3% of annotations had no ontological counterpart in another physician’s rendering. The model summarised 16,600 HPO terms into 390 groups of co-occurring symptoms and covered 11,340 (98.4%) of the cohort associations. Of 28,862 associations added to the HPO between 2022 and 2025, 34.8% had been predicted by the factorisation in 2022. PhenoGenius reduced the median rank of the causal gene from 65 with the best comparator (CADA) to 35, an advantage reproduced in each of the four cohorts, and recovered the causal gene within the top 500 in 87.0% of patients, against 81.6%. On curated case reports, the causal gene ranked within the top 10 in 48.6% of cases. Symptom co-occurrence modelling captures the variability of real-world phenotyping and extends the coverage of phenotype-driven gene prioritisation, offering a scalable approach to support genomic diagnosis and precision medicine.
No takes yet. Share an insight, caveat, or question.
Yauy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: